Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02666001 · ClinicalTrials.gov registry record · Phase 1

A Study to Assess the Drug-drug Interaction of BMS 663068 With Methadone and Also With Buprenorphine/Naloxone

A Phase 1 study, sponsored by ViiV Healthcare.

Completed
Registry status
Phase 1
Development phase
32
Enrollment target

NCT02666001 is a Phase 1 study that has completed, run by ViiV Healthcare. The registered enrollment target is 32 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02666001, a Phase 1 study, has completed, sponsored by ViiV Healthcare.

COMPLETED
Registry status
Phase 1
Development phase
32 participants
Enrollment target

Study Summary

The study is being conducted to assess the effect of multiple doses of BMS-663068 on the exposure of methadone in subjects on a stable dose of methadone, and the exposure of buprenorphine and norbuprenorphine in subjects on a stable dose of buprenorphine and norbuprenorphine.

Interventions

  • DRUG Methadone
  • DRUG BMS-663068
  • DRUG Buprenorphine and Norbuprenorphine

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2016-01-12
Est. Completion 2016-06-29
Phase Phase 1

Sponsor

ViiV Healthcare

182 total trials

What the Registry Record Tells You About NCT02666001

The ClinicalTrials.gov registry entry for NCT02666001 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ViiV Healthcare, which has 182 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which Methadone is the first listed.

NCT02666001 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02666001 about?

NCT02666001 is a clinical study titled "A Study to Assess the Drug-drug Interaction of BMS 663068 With Methadone and Also With Buprenorphine/Naloxone". The study is being conducted to assess the effect of multiple doses of BMS-663068 on the exposure of methadone in subjects on a stable dose of methadone, and the exposure of buprenorphine and norbuprenorphine in subjects on a stable dose of buprenorphine and norbuprenorphine.

What is the current status of trial NCT02666001?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2016-01-12. Estimated completion is 2016-06-29.

What interventions are being tested in trial NCT02666001?

The interventions under investigation include: Methadone (DRUG), BMS-663068 (DRUG), Buprenorphine and Norbuprenorphine (DRUG).

Who is sponsoring clinical trial NCT02666001?

This trial is sponsored by ViiV Healthcare, which has 182 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.